Align Technology, Inc. ALGN SPX
Align Technology, Inc. provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers Invisalign comprehensive package to treat adults and teens malocclusion and features, and orthodontic needs of teenage or younger patients; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients between the ages of six and ten years with a mixture of primary/baby and permanent teeth. This segment also provides Invisalign express, Invisalign lite, and Invisalign moderate; Invisalign Go, Invisalign Go express, and Invisalign Go Plus; retention products, Invisalign training, adjusting tools used by dental professionals during treatment, ancillary Invisalign accessory products, and other oral health products; Invisalign Professional Whitening system; Invisalign Palatal Expander, a 3D printed orthodontic device; and 3D printing solutions. Its Imaging Systems and CAD/CAM Services segment offers iTero intraoral scanning system, a single hardware platform for restorative or orthodontic procedures; exocad, a computer-aided design and computer-aided manufacturing software; orthodontist software for digital records storage, orthodontic diagnosis, and fabrication of printed models and retainers; and restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons. This segment also offers Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; Align Oral Health Suite, a digital interface for dental consultations; iTero TimeLapse technology for doctors or practitioners to compare a patient's historic 3D scans to the present-day scan; and subscription software, disposables, rents scanners, and pay per scan services. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALGN Align Technology, Inc. SPX | 174.95 | 29.40 | $12.53B | - | 13.57% | 10.82% | 2.61% | 4.31% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 436.92M | 490.26M | 505.29M | 548.97M | 600.70M | 607.34M | 550.96M | 352.31M | 734.14M | 894.77M | 1.01B | 1.02B | 973.22M | 969.55M | 890.35M | 943.15M | 1.00B | 960.21M | 997.43M | 1.03B | - | - | 979.26M | 1.01B | 995.69M | 1.05B | 1.04B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 299.15M | 304.33M | 356.49M | 363.97M | 303.50M |
| Gross Profit | 125.09M | 137.25M | 145.48M | 145.05M | 151.09M | 158.63M | 157.58M | 180.63M | 205.22M | 209.20M | 235.62M | 270.92M | 292.49M | 327.41M | 365.58M | 371.78M | 402.10M | 432.29M | 437.55M | 394.36M | 224.33M | 534.09M | 677.10M | 758.54M | 755.16M | 709.35M | 687.56M | 619.17M | 660.65M | 713.61M | 663.08M | 697.82M | 722.63M | - | - | 680.11M | 708.12M | 639.20M | 683.59M | 736.59M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 544.83M | 545.08M | 511.08M | 524.71M | 564.00M |
| Operating Income | 41.46M | 41.80M | 48.73M | 51.55M | 48.92M | 42.33M | 38.05M | 53.33M | 65.14M | 62.08M | 61.67M | 83.57M | 98.76M | 98.19M | 122.69M | 125.21M | 87.70M | 176.49M | 127.15M | 69.92M | -73.00M | 177.07M | 225.45M | 268.90M | 261.16M | 198.08M | 188.20M | 143.66M | 133.52M | 171.93M | 166.35M | 154.13M | 147.05M | - | - | 135.28M | 163.03M | 128.12M | 158.88M | 172.59M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 174.43M | 203.61M | 183.84M | 260.87M | 229.13M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 140.44M | 173.52M | 94.73M | 176.59M | 148.89M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.21M | 48.91M | 37.98M | 40.84M | 36.12M |
| Net Income | 34.54M | 32.44M | 35.60M | 38.25M | 36.18M | 31.35M | 27.62M | 40.55M | 50.15M | 51.37M | 69.42M | 69.18M | 82.56M | 95.87M | 106.11M | 100.87M | 71.85M | 147.14M | 102.52M | 1.52B | -40.60M | 139.37M | 200.38M | 199.71M | 180.97M | 134.30M | 112.80M | 72.70M | 87.80M | 111.81M | 121.43M | 105.03M | 96.56M | - | - | 93.23M | 124.61M | 56.75M | 135.76M | 112.77M |
| Diluted EPS | 0.42 | 0.39 | 0.43 | 0.47 | 0.44 | 0.39 | 0.34 | 0.50 | 0.62 | 0.63 | 0.85 | 0.85 | 1.01 | 1.17 | 1.30 | 1.24 | 0.89 | 1.83 | 1.28 | 19.21 | -0.52 | 1.76 | 2.51 | 2.51 | 2.28 | 1.70 | 1.44 | 0.93 | 1.14 | 1.46 | 1.58 | 1.39 | 1.28 | - | - | 1.27 | 1.72 | 0.78 | 1.89 | 1.57 |
| R&D Expense | 10.91M | 13.38M | 13.29M | 12.85M | 13.88M | 15.68M | 17.78M | 15.08M | 18.61M | 20.41M | 22.80M | 24.38M | 24.20M | 29.59M | 30.80M | 32.70M | 37.50M | 38.85M | 39.68M | 41.53M | 40.36M | 44.53M | 54.54M | 57.72M | 65.59M | 71.81M | 72.97M | 76.97M | 87.45M | 88.48M | 88.74M | 91.86M | 92.19M | 85.27M | - | 97.20M | 96.40M | 93.28M | - | 98.66M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 1.08B | 1.47B | 1.97B | 2.41B | 2.47B | - | 3.73B | 3.86B | 4.00B | 4.03B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.10B | 1.16B | 1.20B | 1.32B |
| Gross Profit | 225.13M | 233.49M | 303.42M | 361.28M | 416.39M | 498.11M | 578.44M | 640.11M | 815.29M | 1.12B | 1.45B | 1.74B | 1.76B | - | 2.63B | 2.71B | 2.80B | 2.71B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.98B | 2.05B | 2.13B | 2.13B |
| Operating Income | 15.51M | -34.01M | 102.73M | 90.36M | 85.59M | 94.21M | 193.58M | 188.63M | 248.92M | 353.61M | 466.56M | 542.49M | 387.17M | - | 654.05M | 656.65M | 671.76M | 585.31M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 779.84M | 799.05M | 816.80M | 822.75M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 599.06M | 641.20M | 608.96M | 585.29M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 237.48M | 196.15M | 187.60M | 174.94M |
| Net Income | 79.99M | -31.27M | 74.25M | 66.72M | 58.69M | 64.30M | 145.83M | 144.02M | 189.68M | 231.42M | 400.24M | 442.78M | 1.78B | - | 361.57M | 445.05M | 421.36M | 410.35M |
| Diluted EPS | 1.18 | -0.45 | 0.95 | 0.83 | 0.71 | 0.78 | 1.77 | 1.77 | 2.33 | 2.83 | 4.92 | 5.53 | 22.41 | - | 4.61 | 5.81 | 5.62 | 5.65 |
| R&D Expense | 26.16M | 22.25M | 26.00M | 37.15M | 42.87M | 44.08M | 52.80M | 61.24M | 75.72M | 97.56M | 128.90M | 157.36M | 175.31M | 250.31M | 305.26M | 346.83M | 364.20M | 369.91M |
Compounded Sales Growth
| 5 Years: | 2.61% |
| 1 Year: | 6.20% |
Compounded Profit Growth
| 5 Years: | 4.31% |
| 1 Year: | 23.90% |
Stock Price Performance
| 1 Year: | -3.31% |
| 6 Months: | +18.61% |
| 3 Months: | -7.97% |
| 1 Month: | -1.93% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 355.24M | 476.94M | 649.26M | 756.31M | 832.15M | 988.00M | 1.16B | 1.40B | 1.78B | 2.05B | 2.50B | 4.83B | - | 5.95B | 6.08B | 6.21B | 6.23B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.42B | 2.45B | 2.49B | 2.62B |
| Cash & Equivalents | 89.12M | 87.10M | 166.49M | 294.66M | 306.39M | 306.39M | 242.95M | 199.87M | 167.71M | 389.27M | 449.51M | 636.90M | 550.42M | 960.84M | - | 942.05M | 937.44M | 1.04B | 1.09B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 338.75M | 296.90M | 254.29M | 226.34M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 859.68M | 903.42M | 995.68M | 1.10B |
| Total Liabilities | - | - | 82.20M | 99.20M | 158.48M | 175.00M | 198.18M | 235.23M | 310.71M | 400.76M | 629.72M | 799.57M | 1.15B | 1.60B | - | 2.35B | 2.45B | 2.36B | 2.18B |
| Current Liabilities | - | - | 81.24M | 92.97M | 148.12M | 155.77M | 175.34M | 201.81M | 271.67M | 354.33M | 500.05M | 692.07M | 970.97M | 1.33B | - | 1.93B | 2.07B | 2.04B | 1.92B |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 126.91M | 126.62M | 119.28M | 114.45M |
| Total Equity | 161.15M | 218.54M | 377.75M | 377.75M | 490.78M | 581.32M | 633.97M | 752.77M | 847.93M | 999.31M | 1.15B | 1.25B | 1.35B | 3.23B | - | 3.60B | 3.63B | 3.85B | 4.05B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 77.27M | 75.08M | 73.85M | 71.36M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 39.75M | 74.17M | 129.53M | 130.47M | 133.78M | 185.98M | 226.90M | 238.00M | 247.65M | 438.54M | 554.68M | 747.27M | 662.17M | - | 568.73M | 785.78M | 738.23M | 593.22M |
| Investing Cash Flow | -1.05M | -1.56M | -15.92M | -211.61M | -78.30M | -210.73M | -201.63M | -166.36M | 73.03M | -251.48M | 6.93M | -350.44M | -231.51M | - | -213.32M | -195.94M | -254.91M | -112.44M |
| Financing Cash Flow | -40.35M | 6.84M | 14.71M | 27.24M | 10.21M | -38.17M | -66.42M | -100.79M | -95.52M | -135.50M | -369.43M | -485.54M | -30.81M | - | -501.69M | -598.34M | -355.72M | -464.58M |
| Capital Expenditure | -14.33M | -7.19M | -18.03M | -30.40M | -38.33M | -19.41M | -24.09M | -53.45M | -70.58M | -195.69M | -223.31M | -149.71M | -154.92M | - | -291.90M | -177.72M | -115.58M | -102.44M |
| Free Cash Flow | 25.41M | 66.97M | 111.50M | 100.06M | 95.44M | 166.56M | 202.81M | 184.55M | 177.08M | 242.84M | 331.37M | 597.56M | 507.26M | - | 276.83M | 608.06M | 622.65M | 490.78M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -146.27M | -8.51M | 127.60M | 16.20M |
| Share Buybacks | 50.14M | - | 0 | 7.75M | 47.20M | 95.11M | 98.23M | 101.79M | 96.22M | 103.79M | 300.00M | 400.00M | 0 | 375.04M | 435.04M | 592.36M | 352.88M | 465.94M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | 75.5% | 75.8% | 73.6% | 72.5% | 71.3% | - | 70.5% | 70.1% | 70.0% | 67.2% |
| Operating Margin % | - | - | - | - | - | - | - | - | 23.1% | 24.0% | 23.7% | 22.5% | 15.7% | - | 17.5% | 17.0% | 16.8% | 14.5% |
| Net Margin % | - | - | - | - | - | - | - | - | 17.6% | 15.7% | 20.4% | 18.4% | 71.8% | - | 9.7% | 11.5% | 10.5% | 10.2% |
| ROE % | 36.6% | -8.3% | 19.7% | 13.6% | 10.1% | 10.1% | 19.4% | 17.0% | 19.0% | 20.0% | 31.9% | 32.9% | 54.9% | - | 10.0% | 12.3% | 10.9% | 10.1% |
| ROCE % | - | -12.4% | 26.8% | 18.0% | 14.3% | 14.3% | 24.6% | 21.3% | 23.9% | 27.5% | 34.3% | 35.5% | 11.0% | - | 16.3% | 16.3% | 16.1% | 13.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 6.13% | 4.39M | $767.88M |
| 2 | Blackrock Inc. | 5.99% | 4.29M | $750.52M |
| 3 | Capital World Investors | 5.69% | 4.07M | $712.45M |
| 4 | Capital International Investors | 5.32% | 3.81M | $666.42M |
| 5 | Vanguard Portfolio Management LLC | 4.40% | 3.15M | $551.23M |
| 6 | FMR, LLC | 3.77% | 2.70M | $472.43M |
| 7 | State Street Corporation | 3.51% | 2.52M | $440.22M |
| 8 | Ninety One UK Ltd | 3.11% | 2.23M | $389.83M |
| 9 | Kayne Anderson Rudnick Investment Management LLC | 2.66% | 1.90M | $332.91M |
| 10 | Goldman Sachs Group Inc | 2.51% | 1.80M | $314.25M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALGN